top of page

Verve Therapeutics' CEO on today's gene editing clinical trial pause

  • Apr 2, 2024
  • 1 min read

Sek Kathiresan describes what Verve believes caused elevated liver enzymes and thrombocytopenia in a PCSK9 gene editing trial and why he thinks a new program set to enter the clinic may avoid these issues.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page